Melanoma Molecular Maps Projects


Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;

  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);

  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.

Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.

The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.


"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

Sphingosine metabolism as a therapeutic target in cutaneous melanoma.
Dany M
Transl Res. 2017 May 4;():.
PMID: 28528915 [PubMed - as supplied by publisher]

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA, Mohr P, Ascierto PA, Arance A, Banos Hernaez A, Kaskel P, Weichenthal M, Shinde R, Stevinson K
Oncologist. 2017 May 19;():.
PMID: 28526721 [PubMed - as supplied by publisher]

Emotional distress and health-related quality of life among cutaneous melanoma follow-up outpatients: the role of self-perception of body image and surgical scarring.
Bassino S, Ribero S, Miniotti M, Picardi A, Caliendo V, Castelli L, Torta R, Macripò G, Leombruni P
Eur J Dermatol. 2017 May 19;():.
PMID: 28524051 [PubMed - as supplied by publisher]

Genetic Variants in the Genes Encoding Rho GTPases and Related Regulators Predict Cutaneous Melanoma-specific Survival.
Liu S, Wang Y, Xue W, Liu H, Xu Y, Shi Q, Wu W, Zhu D, Amos CI, Fang S, Lee JE, Hyslop T, Li Y, Han J, Wei Q
Int J Cancer. 2017 May 16;():.
PMID: 28510328 [PubMed - as supplied by publisher]

Cutaneous melanoma in women.
Roh MR, Eliades P, Gupta S, Grant-Kels JM, Tsao H
Int J Womens Dermatol. 2017 Mar;3(1 Suppl):S11-S15.
PMID: 28492033 [PubMed - in process]

NCBI's Disclaimer and Copyright notice